Cargando…

Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma

Drug resistance imposes severe limitations to the efficacy of targeted therapy in BRAF-mutated metastatic melanoma. Although this issue has been mitigated by the development of combination therapies with BRAF plus MEK inhibitors, drug resistance inevitably occurs with time and results in clinical re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fattore, Luigi, Ruggiero, Ciro Francesco, Pisanu, Maria Elena, Liguoro, Domenico, Cerri, Andrea, Costantini, Susan, Capone, Francesca, Acunzo, Mario, Romano, Giulia, Nigita, Giovanni, Mallardo, Domenico, Ragone, Concetta, Carriero, Maria Vincenza, Budillon, Alfredo, Botti, Gerardo, Ascierto, Paolo Antonio, Mancini, Rita, Ciliberto, Gennaro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6748102/ https://www.ncbi.nlm.nih.gov/pubmed/30254376 http://dx.doi.org/10.1038/s41418-018-0205-5

Ejemplares similares

ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine Neuregulin
por: Ruggiero, Ciro Francesco, et al.
Publicado: (2019)

Single cell analysis to dissect molecular heterogeneity and disease evolution in metastatic melanoma
por: Fattore, Luigi, et al.
Publicado: (2019)

In Vitro Biophysical and Biological Characterization of Lipid Nanoparticles Co-Encapsulating Oncosuppressors miR-199b-5p and miR-204-5p as Potentiators of Target Therapy in Metastatic Melanoma
por: Fattore, Luigi, et al.
Publicado: (2020)

The Promise of Liquid Biopsy to Predict Response to Immunotherapy in Metastatic Melanoma
por: Fattore, Luigi, et al.
Publicado: (2021)

Structure-function relationship of an Urokinase Receptor-derived peptide which inhibits the Formyl Peptide Receptor type 1 activity
por: Minopoli, Michele, et al.
Publicado: (2019)

Reverse transcriptase inhibition potentiates target therapy in BRAF-mutant melanomas: effects on cell proliferation, apoptosis, DNA-damage, ROS induction and mitochondrial membrane depolarization
por: Fattore, Luigi, et al.
Publicado: (2020)

Identification of a miRNA-based non-invasive predictive biomarker of response to target therapy in BRAF-mutant melanoma
por: Ruggiero, Ciro Francesco, et al.
Publicado: (2022)

Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells
por: Ragone, Concetta, et al.
Publicado: (2017)

Retro-inverso Urokinase Receptor Antagonists for the Treatment of Metastatic Sarcomas
por: Carriero, Maria Vincenza, et al.
Publicado: (2017)

MicroRNAs in melanoma development and resistance to target therapy
por: Fattore, Luigi, et al.
Publicado: (2017)

Upregulated expression of miR-4443 and miR-4488 in drug resistant melanomas promotes migratory and invasive phenotypes through downregulation of intermediate filament nestin
por: Castaldo, Vittorio, et al.
Publicado: (2023)

Oncosuppressive miRNAs loaded in lipid nanoparticles potentiate targeted therapies in BRAF-mutant melanoma by inhibiting core escape pathways of resistance
por: Fattore, Luigi, et al.
Publicado: (2022)

Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma
por: Pisanu, Maria Elena, et al.
Publicado: (2018)

MMP-9 as a Candidate Marker of Response to BRAF Inhibitors in Melanoma Patients With BRAF(V600E) Mutation Detected in Circulating-Free DNA
por: Salemi, Rossella, et al.
Publicado: (2018)

Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations
por: Ascierto, Paolo A., et al.
Publicado: (2019)

Targeting the Formyl Peptide Receptor type 1 to prevent the adhesion of ovarian cancer cells onto mesothelium and subsequent invasion
por: Minopoli, Michele, et al.
Publicado: (2019)

ErbB3 plays a key role in the early phase of establishment of resistance to BRAF and/or MEK inhibitors
por: Fattore, Luigi, et al.
Publicado: (2015)

Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma
por: Fattore, Luigi, et al.
Publicado: (2015)

A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation
por: Simeone, Ester, et al.
Publicado: (2021)

Role of Microenvironment on the Fate of Disseminating Cancer Stem Cells
por: Ingangi, Vincenzo, et al.
Publicado: (2019)

AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
por: Caputo, Emilia, et al.
Publicado: (2014)

Tumor biobanks in translational medicine
por: Botti, Gerardo, et al.
Publicado: (2012)

Potential Anticancer Effects of Polyphenols from Chestnut Shell Extracts: Modulation of Cell Growth, and Cytokinomic and Metabolomic Profiles
por: Sorice, Angela, et al.
Publicado: (2016)

Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells
por: Fratangelo, Federica, et al.
Publicado: (2018)

Activation of the ErbB3-AKT axis promotes melanoma cell survival and proliferation in response to RAF/MEK inhibition
por: Fattore, Luigi, et al.
Publicado: (2014)

Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies
por: Fattore, Luigi, et al.
Publicado: (2013)

Cancer Stem Cells and the Slow Cycling Phenotype: How to Cut the Gordian Knot Driving Resistance to Therapy in Melanoma
por: Fattore, Luigi, et al.
Publicado: (2020)

Identifying a panel of genes/proteins/miRNAs modulated by arsenicals in bladder, prostate, kidney cancers
por: Polo, Andrea, et al.
Publicado: (2018)

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas
por: Manca, Antonella, et al.
Publicado: (2015)

MISIPI study: Melanoma ImmunoScore evaluation in patients treated with IPIlimumab
por: Bifulco, Carlo, et al.
Publicado: (2014)

The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment
por: Ascierto, Paolo A, et al.
Publicado: (2013)

Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma
por: Colombino, Maria, et al.
Publicado: (2013)

Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab
por: Morello, Silvana, et al.
Publicado: (2017)

Immunoscore: a new possible approach for melanoma classification
por: Capone, Mariaelena, et al.
Publicado: (2014)

An Integrated In Silico, In Vitro and Tumor Tissues Study Identified Selenoprotein S (SELENOS) and Valosin-Containing Protein (VCP/p97) as Novel Potential Associated Prognostic Biomarkers in Triple Negative Breast Cancer
por: Costantini, Susan, et al.
Publicado: (2022)

Serum Cytokinome Profile Evaluation: A Tool to Define New Diagnostic and Prognostic Markers of Cancer Using Multiplexed Bead-Based Immunoassays
por: Capone, Francesca, et al.
Publicado: (2016)

AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
por: Caputo, Emilia, et al.
Publicado: (2015)

New Insights into the Identification of Metabolites and Cytokines Predictive of Outcome for Patients with Severe SARS-CoV-2 Infection Showed Similarity with Cancer
por: Costantini, Susan, et al.
Publicado: (2023)

The Ratio of GrzB(+) − FoxP3(+) over CD3(+) T Cells as a Potential Predictor of Response to Nivolumab in Patients with Metastatic Melanoma
por: Scognamiglio, Giosuè, et al.
Publicado: (2021)

Integrated Analysis to Study the Relationship between Tumor-Associated Selenoproteins: Focus on Prostate Cancer
por: Capone, Francesca, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0n54b63cbbqfoqeoi82mnb07h2